VIVS VivoSim Labs Inc.

Price (delayed)

$0.286

Market cap

$4.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.47

Enterprise value

$2.75M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 0
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 15

Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, ...

Highlights
VIVS's debt has dropped by 62% year-on-year and by 44% since the previous quarter
The EPS has increased by 16% since the previous quarter
The equity has dropped by 125% year-on-year and by 113% since the previous quarter
VIVS's quick ratio has plunged by 68% YoY and by 32% from the previous quarter

Key stats

What are the main financial stats of VIVS

VIVS stock price

How has the VivoSim Labs stock price performed over time
Intraday
3.06%
1 week
-11.32%
1 month
-36.44%
1 year
-85.56%
YTD
-84.2%
QTD
-73.27%

Financial performance

How have VivoSim Labs's revenue and profit performed over time
Revenue
$112,000
Gross profit
$112,000
Operating income
-$11.33M
Net income
-$12.34M
Gross margin
100%
Net margin
-11,016.1%
The revenue has contracted by 21% YoY and by 15% from the previous quarter
VIVS's gross profit is down by 19% year-on-year and by 15% since the previous quarter
The operating margin has declined by 18% year-on-year and by 15% since the previous quarter
The net income is up by 11% since the previous quarter

Price vs fundamentals

How does VIVS's price correlate with its fundamentals

Growth

What is VivoSim Labs's growth rate over time

Valuation

What is VivoSim Labs stock price valuation
P/E
N/A
P/B
N/A
P/S
13.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.56
The EPS has increased by 16% since the previous quarter
The equity has dropped by 125% year-on-year and by 113% since the previous quarter
The P/S is 71% below the 5-year quarterly average of 45.4 and 68% below the last 4 quarters average of 41.5
The revenue has contracted by 21% YoY and by 15% from the previous quarter

Efficiency

How efficient is VivoSim Labs business performance
The ROE has plunged by 121% from the previous quarter
VIVS's return on invested capital is down by 21% since the previous quarter
VIVS's return on assets is down by 15% since the previous quarter
The ROS has declined by 4.2% since the previous quarter

Dividends

What is VIVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIVS.

Financial health

How did VivoSim Labs financials performed over time
The total assets is 38% smaller than the total liabilities
The total liabilities has surged by 154% year-on-year but it has declined by 27% since the previous quarter
The total assets has dropped by 68% year-on-year and by 48% since the previous quarter
VIVS's debt is 113% greater than its equity
The equity has dropped by 125% year-on-year and by 113% since the previous quarter
The debt to equity has soared by 75% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.